425 Summer Street,

Boston,

MA,

US,

ZIP: 02210

Phone: +1 6174554188

With two approved therapeutics and the field working to develop the next generation of IPF drugs, the opportunity to become the undisputed, most effective, and disease-modifying agent on the market has never been greater.

Packed with 4 days of insightful content, the IPF Summit is back in Boston to help you delve into the persistent translational and clinical challenges in the space.

This industry’s undisputed forum will unite 150+ industry giants and pioneering academics in-person including Boehringer Ingelheim, Genentech, Novartis, AbbVie, Gilead, Fernando Martinez, Naftali Kaminski, Toby Maher, and many more. Join them to gain end-to-end insights to empower you with the knowledge you need for your 2022/2023 IPF research and drug development goals.

Organizations across autoimmunity, regenerative medicine, and inflammation are turning towards IPF as a strategic opportunity. Attend this dynamic meeting filled with formal presentations, interactive workshops, panel discussions, and organized networking to fast track your understanding, strategize success, and advance the IPF drug development frontier.

Tickets    https://go.evvnt.com/1139535-2?pid=1052
Brochure https://go.evvnt.com/1139535-3?pid=1052

Prices:
Industry - Conference + Pre AND Post Conference Day USD 4797.00
Industry - Conference + Pre OR Post Conference Day USD 3898.00
Industry - Conference Only USD 2999.00
Academic - Conference + Pre AND Post Conference Day USD 4197.00
Academic - Conference + Pre OR Post Conference Day USD 3398.00
Academic - Conference Only USD 2599.00
Service Provider - Conference + Pre AND Post Conference Day USD 5597.00
Service Provider - Conference + Pre OR Post Conference Day USD 4598.00
Service Provider - Conference Only USD 3599.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Adbulkader Rahmo, President & Chief Scientific Officer, SMSBiotech, Andrew Haak, Assistant Professor, Mayo Clinic, Bassem Elmankabadi, Senior Vice President, Blade Therapeutics, Bertil Lindmark, Chief Medical Officer, Galecto Biotech, Brian Windsor, Chief Executive Officer, Lung Therapeutics, Carolyn Baglole, Associate Professor, McGill University, Diana Julia Leeming, Director of Fibrosis, Hepatic & Pulmonary Research, Nordic Bioscience, Eric White, Senior Clinical Program Lead, Boehringer Ingelheim, Fernando Martinez, Chief of the Pulmonary and Critical Care Medicine Division, Weill Cornell Medical College, Gary Hunninghake, Associate Professor, Harvard Medical School, Glenn Rosen, Chief Scientific Officer, Optikira LLC and Anteros Therapeutics, Hana Cernecka, Head of Inflammation, Bayer, Heike Fuhrmann, Stroissnigg Senior Scientist – Research, Gilead, Jeffrey Horowitz, Professor, Ohio State University, Johan Raud, Chief Scientific Officer, Vicore Pharma Holding, Joyce Lee, Associate Professor, University of Colorado Denver, Kjetil Ask, Associate Professor, McMaster University, Kostas Alysandratos, Assistant Professor, Boston University, Kristen Browder, Principal Scientific Researcher, Genentech, Larry Tsai, Global Head of Respiratory & Rheumatology Product Development, Genentech, Lida Hariri, Assistant Professor Massachusetts General Hospital, Harvard Medical School, Lisa Hazelwood, Senior Principal Research Scientist, AbbVie, Lorna Harries, Chief Scientific Officer, Senisca, Lydia Gilbert, McClain Principal, LVM Pharmaceuticals Consulting, Majd Mouded, Executive Director, Novartis, Marilyn K. Glassberg, The John W. Clarke Professor of Medicine, Chair, Department of Medicine, Loyola University, Marina Pavlidou, Global Project Leader, Pieris Pharmacetuicals, Mark Eisner, Chief Medical Officer, FibroGen, Mark Surber, Chief Scientific Officer, Avalyn Pharma, Martin Kolb Director, Division of Respirology, McMaster University, Matt Bradley, Chief Executive Officer, Saje Pharma, Matthew Thomas, Head of Respiratory Exploratory Innovation, Boehringer Ingelheim, Meghan Clements, Principal Scientist II, AbbVie, Michelle Chen, Chief Business Officer, Insilico, Moty Klepfish, Principal Scientist, Fibrosis, Anima Biotech, Naftali Kaminski, Professor, Yale School of Medicine, Oliver Eickelberg, Professor of Medicine & Vice Chair of Basic & Translational Sciences, University of Pittsburgh, Patricia Sime, Professor, Virginia Commonwealth University, Peter Schafer, Vice President, Bristol Myers Squibb, Peter Smith, Vice President – Product Development, United Therapeutics, Steven Duncan, Professor, University of Alabama at Birmingham, Taylor Adams, Associate Professor, Yale School of Medicine, Toby Maher, Professor, University of Southern California, Tom Sciascia, Chief Medical Officer, Trevi Therapeutics, Viktor Thannickal, Professor, Tulane University School of Medicine, William Forbes, Chief Development Officer, Trevi Therapeutics, Yasmina Bauer, Head of Clinical Biomarkers, Galapagos, Zbigniew Zaslona, Vice President & Head of Research Biology, Molecure